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Abstract
Background: Fat abnormalities are common among HIV-infected persons, but few studies have
compared regional body fat distribution, including visceral fat, in HIV-infected and HIV-uninfected
persons and their subsequent trajectories in body composition over time.
Methods: Between 1999 and 2002, 33 men with clinical evidence of lipodystrophy (LIPO+), 23
HIV-infected men without clinical evidence of lipodytrophy (LIPO-), and 33 HIV-uninfected men
were recruited from the four sites of the Multicenter AIDS Cohort Study (MACS). Participants
underwent dual-energy x-ray absorptiometry, quantitative computerized tomography of the
abdomen and thigh, and circumference measurements of the waist, hip and thigh. Circumference
measurements at each semi-annual MACS visit between recruitment and 2008 were used to
compare average annual anthropometric changes in the 3 groups.
Results: Body mass index (BMI) was lower in LIPO+ men than in the LIPO- men and the HIV-
uninfected controls (BMI: 23.6 ± 0.4 vs 26.8 ± 1.5 vs 28.7 ± 0.9 kg/m2, respectively, p < 0.001). The
average amount of visceral adipose tissue (VAT) was similar in all three groups (p = 0.26), but after
adjustment for BMI, VAT was higher in the LIPO+ group (169 ± 10 cm2) compared to the LIPO-
men (129 ± 12 cm2, p = 0.03) and the HIV-uninfected group (133 ± 11 cm2, p = 0.07). Subcutaneous
adipose tissue (thigh, abdomen) and total extremity fat were less in the HIV-infected men (LIPO+
and LIPO-) than in the HIV-uninfected men. Over an average of 6 years of follow-up, waist
circumference increased at a faster rate in LIPO+ group, compared to the LIPO- men (0.51 cm/
year vs 0.08 cm/year, p = 0.02) and HIV-uninfected control men (0.21 cm/year, p = 0.06). The
annual changes in hip and thigh circumferences were similar in all three groups
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Conclusion: Subcutaneous lipoatrophy was observed in HIV-infected patients, even those without
clinical evidence of lipodystrophy, compared to age-matched HIV-uninfected men. Despite
markedly lower BMI, HIV-infected men with lipodystrophy had a similar amount of VAT as HIV-
uninfected men and tended to have more rapid increases in waist circumference over 6 years of
follow-up. These longitudinal increases in waist circumference may contribute to the development
of cardiovascular risk in HIV-infected patients with lipodystrophy.
Introduction
In the era of highly active antiretroviral therapy (HAART),
body habitus changes occur frequently among HIV-
infected patients[1]. These include lipohypertrophy of the
visceral compartment, breasts, and the upper back (dor-
socervical fat pad) and subcutaneous lipoatrophy of the
trunk, face and extremities. Studies of risk factors for the
development of lipohypertrophy and lipoatrophy have
generally evaluated only HIV-infected patients[2]. How-
ever, in order to ascertain the uniqueness and relative clin-
ical importance of body composition changes that occur
among HIV-infected patients, comparison to a HIV-unin-
fected control group is essential. Cross-sectional studies
assessing cardiometabolic risk in HIV-infected patients
have demonstrated greater waist circumferences[3] and
waist:hip ratios [4], but smaller hip and thigh circumfer-
ences[3], compared to well-characterized HIV-uninfected
control populations.
Relatively few studies, however, have compared fat distri-
bution in HIV-infected and HIV-uninfected individuals
using techniques that can separate subcutaneous and vis-
ceral fat in the abdomen, such as quantitative computer-
ized tomography (CT) or magnetic resonance imaging
(MRI). The largest study to date that has compared body
composition in HIV-infected men and women to HIV-
uninfected controls is the Study of Fat Redistribution and
Metabolic Change in HIV Infection (FRAM). Data from
this study indicated that HIV-infected men and women
with clinical lipoatrophy had less visceral adipose tissue
(VAT) than HIV-uninfected controls[5,6]. Another large
cross-sectional study also described less peripheral fat, but
more VAT, in HIV-infected versus HIV-uninfected women,
despite similar average body mass indices (BMI) in both
groups[7].
Even fewer studies have compared longitudinal changes
in body composition in HIV-infected and HIV-uninfected
individuals. In the Multicenter AIDS Cohort Study
(MACS), we found that waist circumference increased
more rapidly in HIV-infected men compared to HIV-unin-
fected men after adjustment for cumulative antiretroviral
exposure, although baseline waist circumference was
markedly lower in HIV-infected men[8]. This more rapid
increase in waist circumference associated with HIV-infec-
tion may represent a "return to health" phenomenon,
whereby effective antiretroviral therapy allows a return to
the pre-morbid body composition and "catch-up" to HIV-
negative peers.
We conducted a substudy in the MACS whose primary
goal was to compare fat distribution, including VAT, in
HIV-infected men with and without lipodystrophy to
HIV-uninfected men using direct quantitative measure-
ments, in addition to anthropomorphic measurements.
Furthermore, to better understand body shape changes
over time, we examined the relationship between these
data and longitudinal changes in anthropometry in these
three groups over the 6 years following the cross-sectional
assessment.
Methods
Study Population
The MACS is an ongoing multicenter (Pittsburgh, PA; Bal-
timore, MD; Chicago, IL and Los Angeles, CA) prospective
cohort study of homosexual and bisexual men who are
followed on a semi-annual basis. Each semi-annual MACS
visit includes a detailed medical history, a physical exam-
ination, and collection of biological specimens. The insti-
tutional review boards at each site approved study
protocols and forms, and each participant provided writ-
ten informed consent both for the overall study and this
substudy.
Sampling methods for the Lipodystrophy Substudy
Beginning in April 1999 (visit 31), each MACS study visit
included anthropomorphic measurements. At that time,
there were 1952 men under observation, including 849
HIV-infected men and 1103 HIV-uninfected men. Partici-
pants for the Lipodystrophy Substudy were recruited
between 1999 and 2002. Cases were identified by stand-
ardized clinical examinations that were completed semi-
annually at each study site, as previously described [9].
HIV-infected men were eligible for recruitment if they
had: 1) mild, moderate, or severe fat atrophy involving
the face, legs, arms, or buttocks, and 2) mild, moderate, or
severe fat hypertrophy involving the breast or abdomen.
"Mild" was defined as "only noted after close inspection".
"Moderate" was defined as fat changes "noticed by the cli-
nician without specifically looking for them". "Severe"
was defined as fat changes "easily noted by a casual
observer."AIDS Research and Therapy 2009, 6:8 http://www.aidsrestherapy.com/content/6/1/8
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Two control groups were recruited: 1) HIV-infected men
without evidence of lipodystrophy by clinical examina-
tion and 2) HIV-uninfected healthy men. Controls were
matched to cases for age within 5 years and by MACS site.
All HIV-infected men were required to have consistently
received the same level of antiretroviral treatment (i.e.,
none, monotherapy or non-HAART combination therapy,
or HAART) during the 2 years prior to study entry. HAART
was defined according to the US Department of Health
and Human Services (DHHS) Kaiser Panel guidelines [10]
as previously described[11]. Men with diabetes mellitus
or who reported using androgens, anabolic steroids, or
other hormonal agents such as megesterol were not eligi-
ble for the substudy.
Of the HIV-infected men under follow-up between 1999
and 2002, 281 met criteria for study entry and could be
evaluated for exclusion criteria. Of these, 135 were
excluded due to use of hormonal agents and 34 due to
diabetes, and 35 due to inconsistent antiretroviral therapy
level in the 2 years preceding the first clinical evidence of
lipodystrophy. Of the remaining 77 men, matched HIV-
infected and HIV-uninfected controls could be found for
60, which constituted the recruitment pool for cases.
Study Procedures
Substudy participants underwent body composition
measurements, including anthropometry, CT of the abdo-
men and thigh, and total body DXA. Body circumferences
(waist, hip, thigh), weight, and height were measured
using the protocol established in the Third National
Health and Nutrition Examination Survey (NHANES
III)[12] by trained examiners, as previously described[8].
A wall-mounted stadiometer was used to measure height.
Each participant was weighed while wearing minimal
clothing or an examination gown. The anthropometric
exam was repeated at each subsequent semi-annual MACS
study visit.
Quantitative CT was used to measure visceral and subcu-
taneous adipose tissue. For the abdominal scan, one axial
image with 3–10 mm slice thickness was obtained using
the space between the fourth and fifth lumbar vertebrae as
the origin point. For the thigh scan, one axial image with
3–10 mm slice thickness was acquired using the midpoint
of the total femur length as the origin point. Images were
sent digitally from each MACS site and were analyzed cen-
trally (Obesity Research Center, Columbia University,
New York) using image analysis software (Tomovision
Inc., Montreal, Canada). Adipose tissue was identified by
selecting the pixels that ranged between -190 and -30
Houndsfield units. The sum of specific tissue pixels multi-
plied by the individual pixel surface area yielded the
respective tissue areas (cm2). Adipose tissue areas were
calculated for visceral adipose tissue (VAT), subcutaneous
adipose tissue (SAT) of the abdomen, and SAT of the
thigh. The coefficient of variation was 2–5%.
Whole body dual-energy x-ray absorptiometry (DXA) was
undertaken to assess whole body tissue composition
(total lean body mass, percent body fat) and regional
body composition (trunk fat, extremity fat). Procedures
were done using a Lunar Prodigy (GE Medical Systems,
Madison, WI) in conjunction with Encore 2002 software
at the Pittsburgh site and Hologic 4500A machines with
QDA4500A software version 9.03 (Hologic Inc, Waltham,
MA) at the other sites.
Statistical analysis
Categorical demographic variables were compared
between the three groups using χ2 testing. Continuous
demographic, anthropometric and body composition var-
iables were compared using analysis of covariance
(ANCOVA), adjusted for the MACS site and race (white vs.
non-white) using PROC GLM in SAS version 9.0 (SAS
Institute, Cary, NC)[13]. Since the HIV-infected men in
the MACS have a lower mean BMI than the HIV-unin-
fected men, as previously noted[9,11], and this may have
confounded the comparison of regional body composi-
tion between the case and the control groups, the data
were also adjusted by 1) by MACS site, race, and BMI; or
2) MACS site, race, and lean body mass. Adjusted means
were obtained via the LS-means option in PROC GLM,
and pairwise comparisons between the groups were made
via t-tests using the pdiff option in the LS-means statement
of PROC GLM.
To determine whether longitudinal changes in anthropo-
morphic measurements differed between the three
groups, multivariable linear mixed effects regression mod-
els were implemented. Measurements that were larger
than the upper quartile + 1.5 (upper quartile – lower quar-
tile) or smaller than the lower quartile – 1.5 (upper quar-
tile – lower quartile) were considered outliers and were
excluded from the analysis. SAS PROC MIXED procedure
with a random intercept was used to account for the cor-
relation of repeated measurements. The dependent varia-
bles were waist, hip, and thigh circumferences. The
independent variables were the study group, BMI at the
baseline visit, MACS site, age centered at 50 yrs, and race.
P-values < 0.05 were considered significant. Longitudinal
changes in anthropometrics for the entire MACS cohort
between 1999 and 2003 have been previously
reported[11].
Results
Substudy Population Characteristics
Eighty-eight men were included from the four MACS sites:
32 HIV-uninfected men, 23 HIV-infected men without
clinical lipodystrophy (LIPO-), and 33 HIV-infected menAIDS Research and Therapy 2009, 6:8 http://www.aidsrestherapy.com/content/6/1/8
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with clinical lipodystrophy (LIPO+). Clinician-generated
severity ratings for lipoatrophy were: 10 (30%) mild, 11
(33%) moderate, and 12 (36%) severe. Severity ratings for
lipohypertrophy were: 9 (27%) mild, 17 (52%) moderate,
and 7 (21%) severe.
Additional file 1 shows the demographic characteristics of
the substudy participants. Age was similar among the
groups. The HIV-uninfected group had a higher propor-
tion of white participants compared to the two HIV-
infected groups. Average BMI and total body fat percent-
age were lowest in the LIPO+ group, intermediate in the
LIPO- group, and highest in the HIV-uninfected group.
Lean body mass tended to be lower in the LIPO+ group
compared to the other two groups.
The LIPO+ group differed from the LIPO- group at the
baseline visit in having a higher proportion of men receiv-
ing HAART, and lower current and nadir CD4 cell counts.
The mean duration of HAART at the time of enrollment
was similar between these two groups.
Computerized Tomography
Additional file 2 shows CT and DXA measurements,
adjusted for: 1) MACS site and race, 2) MACS site, race
and BMI, and 3) MACS site, race and lean body mass. VAT
was similar among the three groups when adjusted for
MACS center and race only. After additional adjustment
for BMI, the mean VAT was higher in the LIPO+ group
compared to the HIV- (p = 0.07) and LIPO- (p = 0.03).
With adjustment for total lean mass, VAT was similar
among the groups (p = 0.11), but tended to be higher in
LIPO+ than the LIPO- group (p = 0.09).
Amounts of subcutaneous adipose tissue in the abdomen
and thigh were lowest in the LIPO+ group, intermediate in
the LIPO- group, and highest in the HIV-uninfected men.
Adjustment for BMI or lean mass reduced the magnitude
of the differences between the groups. After adjustment
for BMI, only the differences between the LIPO+ and HIV-
uninfected groups remained significant. After adjustment
for lean body mass, differences in abdominal SAT were
significant between the HIV-uninfected group and the two
HIV-infected groups. For thigh SAT, the LIPO+ group was
found to have less fat compared to the HIV-infected and
LIPO- groups, and thigh SAT tended to be lower in the
LIPO- group compared to the HIV-uninfected group (p =
0.06).
Dual-energy X-ray Absorptiometry
Additional file 2 shows regional body composition meas-
urements as assessed by DXA. Amounts of trunk fat were
higher in the HIV-uninfected group compared to the
LIPO+ and LIPO- groups. After adjustment for BMI, only
the difference between the HIV-uninfected group and the
LIPO- group remained significant. After adjustment for
lean mass, trunk fat was significantly lower in the HIV-
uninfected group than the two HIV-infected groups.
Extremity fat was lowest in the LIPO+ group, intermediate
in the LIPO- group, and highest in the HIV-uninfected
group. After adjustment for BMI, the differences among
the groups became smaller and either non-significant
(LIPO+ vs. LIPO- groups) or borderline significant (LIPO-
vs. HIV-uninfected group). After adjustment for lean body
mass, the amount of extremity fat was significantly lower
in the LIPO- group compared to the HIV-uninfected
group.
Anthropomorphic data
Additional file 3 shows the anthropometric data in the
three groups. The average waist circumference was highest
among HIV-uninfected men; this was significant after
adjustment for lean body mass but not for BMI.
Hip circumference was lowest in the LIPO+ group, inter-
mediate in the LIPO- group, and highest in the HIV-unin-
fected group. After adjustment for BMI, the differences
between the HIV-uninfected and each of the HIV-infected
groups remained statistically significant. Thigh circumfer-
ence was lower in both of the HIV-infected groups com-
pared to the HIV-uninfected group, regardless of the
adjustment made.
Figure 1 shows the average rates of change in waist, hip
and thigh circumferences over a median of 6 years of fol-
low-up, adjusted for MACS site, age, race, and baseline
BMI. Average waist circumference (± standard error)
increased significantly in the LIPO+ group (0.51 ± 0.12
cm/year, p < 0.0001), increased borderline significantly in
the HIV-uninfected group (0.21 ± 0.11 cm/year, p = 0.07),
and did not change in the LIPO- group (0.08 ± 0.15 cm/
year, p = 0.59). In contrast, hip circumference did not
change significantly in any of the groups, and thigh cir-
cumference decreased slightly, but similarly in all groups
Discussion
In this nested case-control study in the MACS, we used
DXA, quantitative CT, and simple anthropometry to com-
pare regional body composition in HIV-infected men with
and without clinical evidence of lipodystrophy to HIV-
uninfected control subjects. VAT was similar in all 3
groups despite marked differences in BMI, and peripheral
lipoatrophy was accentuated in HIV-infected men, regard-
less of clinical evidence of lipodystrophy, compared to
HIV-uninfected men. Finally, over 6 years of follow-up
waist circumference increased more rapidly in HIV-
infected men who had clinical evidence of lipodystrophy,
compared to the HIV-infected men without lipodystrophyAIDS Research and Therapy 2009, 6:8 http://www.aidsrestherapy.com/content/6/1/8
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and HIV-uninfected men, whereas rate of change in hip
and thigh circumference did not differ by group.
While multiple studies have shown that HIV-infected
patients with lipodystrophy have more VAT than HIV-
infected patients without body composition changes
[14,15], relatively few studies have compared VAT in HIV-
infected and HIV-uninfected populations [5,16]. One of
the difficulties in these comparisons is that BMI tends to
be higher in HIV-uninfected populations compared to
otherwise similar HIV-infected populations, which may
be attributable to differences in energy expendi-
ture[17,18], lipoatrophy, and/or lower lean body mass as
a result of chronic HIV infection[19]. In general, VAT
tends to be higher in a population with a higher BMI,
because of differences in overall adiposity. However,
because of lipoatrophy and possibly latent sarcopenia,
VAT relative to BMI may be magnified in HIV-infected
subjects, posing additional challenges in understanding
differences in VAT between HIV-infected and -uninfected
subjects.
Cross-sectional studies have taken different approaches to
this problem. The FRAM study, the largest such study
comparing body composition in men and women with
and without HIV infection, reported similar amounts of
VAT in 926 HIV-infected and 258 HIV-uninfected sub-
jects[20]. Body mass index, however, was significantly
higher in the HIV-uninfected subjects (27.4 ± 5.2 kg/m2
vs. 25.1 ± 4.4 kg/m2, p < 0.0001). In some FRAM analy-
ses[5], the differences in body size were accounted for by
adjusting for height or lean body mass measured by MRI.
In these analyses, differences in VAT by HIV-status were
gender-dependent: HIV-infected women without clinical
lipoatrophy had more VAT than HIV-infected women
with lipoatrophy or HIV-negative controls[6], while HIV-
infected men without clinical lipoatrophy tended to have
more VAT than HIV-infected men with lipoatrophy, but
less than HIV-uninfected controls[5]. Adjustment for
body size did not change these relationships. In another
cross-sectional study, Joy and colleagues compared
regional fat composition, including VAT, in 306 HIV-
infected subjects (70% of whom were categorized as hav-
ing lipodystrophy), and 107 HIV-uninfected controls[16].
To account for the differences in BMI between the two
groups, the authors stratified their analysis by BMI cate-
gory, arguing that, "weight itself may influence the
amount of adipose tissue present". In this analysis, both
normal weight and overweight HIV-infected men and
women had more VAT than gender-matched, HIV-unin-
fected controls.
In the present study, as in the MACS as a whole [11], HIV-
infected men had lower BMIs than HIV-uninfected men.
Nevertheless, VAT was similar between the HIV-infected
and uninfected groups. To understand the extent to which
the similar VAT levels were confounded by the marked
differences in body mass, we adjusted for lean body mass
as was done in the FRAM study, and this did not alter the
lack of difference between the groups. We also adjusted
for BMI and found that the differences between HIV-
infected men with lipodystrophy and the other two
groups were magnified, the largest difference being that
between the two HIV-infected groups. In addition, men
with clinical evidence of lipodystrophy tended to have
higher VAT than the HIV-uninfected control men after
adjustment for BMI.
Average annual changes (2002–2008) in waist (a), hip (b), and thigh (c) circumferences in HIV-uninfected control men (HIV-),  HIV-infected men without clinical evidence of lipodystrophy (HIV+LIPO-), and HIV-infected with clinical evidence of lipodys- trophy (HIV+LIPO+) Figure 1
Average annual changes (2002–2008) in waist (a), hip (b), and thigh (c) circumferences in HIV-uninfected con-
trol men (HIV-), HIV-infected men without clinical evidence of lipodystrophy (HIV+LIPO-), and HIV-infected 
with clinical evidence of lipodystrophy (HIV+LIPO+). Error bars represent 95% confidence intervals. Results are 
adjusted for baseline BMI, age, race, and MACS site.
(a)                                                   (b)                                                           (c) 
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Consistent with the report by Joy et al, which used strati-
fication, our findings suggest that HIV-infected men with
clinical lipodystrophy tend to have more VAT for a given
BMI than HIV-uninfected men. Because apparent differ-
ences in VAT between HIV-infected and -uninfected per-
sons after matching, adjusting, or stratifying on BMI may
be inflated, the FRAM investigators did not directly adjust
for BMI in their analyses, noting that "BMI is being influ-
enced by the phenomenon being studied: quantity of
fat"[5]. Nevertheless, our findings and those of Joy et al
have important implications for the clinician. In both
HIV-infected and -uninfected populations, increased VAT
is associated with cardiovascular risk factors, such as insu-
lin resistance, low HDL cholesterol, and high triglycerides
[20-23], and in the general population higher VAT is asso-
ciated with incident diabetes mellitus and cardiovascular
disease[24,25]. Clinicians should be aware that some
HIV-infected patients, even at a relatively normal BMI,
may be at increased risk of adverse metabolic and cardio-
vascular outcomes attributable to excess VAT.
Our second major finding was that SAT (thigh or abdo-
men) and extremity fat were markedly lower in HIV-
infected men, with or without clinical lipodystrophy,
compared to HIV-uninfected controls. After adjustment
for BMI or lean body mass, the magnitude and statistical
significance of these differences decreased, with differ-
ences in thigh SAT between the HIV-infected men without
lipodystrophy and the HIV-uninfected group no longer
being statistically significant. However, by DXA, extremity
fat in HIV-infected men without lipodystrophy was 20–
30% lower than in HIV-uninfected men, regardless of the
adjustment. This is consistent with the FRAM study, in
which HIV-infected subjects with and without clinical
lipoatrophy had lower leg fat than HIV-uninfected sub-
jects [5,6]. Taken together, these results underscore the
fact that significant lipoatrophy may be present in HIV-
infected persons without clinical evidence of fat wasting
and highlight the limitations of using a dichotomous def-
inition of lipoatrophy. Further studies should focus on
continuous, objective measures in determining longitudi-
nal changes of body composition in HIV-infected persons
and the potential metabolic consequences of mild, sub-
clinical fat wasting.
Few longitudinal data are available on changes in body
composition in HIV-infected men with and without clini-
cal lipodystrophy, relative to HIV-uninfected persons. In
this study, semi-annual body circumference measure-
ments were available over the 6 years after the substudy
visit. HIV-infected men who had clinical evidence of lipo-
dystrophy had a more rapid increase in waist circumfer-
ence compared to the HIV-infected men without
lipodystrophy, and HIV-uninfected men. In contrast, no
differences were observed between the groups in the
change in hip or thigh circumference over the 6 year inter-
val.
Because measurement of waist circumference does not
distinguish between visceral and subcutaneous fat, the
more rapid increase in waist circumference in the HIV-
infected men with clinical evidence of lipodystrophy
could be due to an expansion of either the subcutaneous
or visceral fat compartments, or both. Given the severity
of lipoatrophy in this group (mean extremity fat 4.5 g), it
is possible that some of this increase is due to a reversal of
abdominal subcutaneous lipoatrophy. However, if this
were the case, more rapid increases in hip and thigh cir-
cumference would have also been expected, and these did
not occur. Further longitudinal studies, such as the FRAM
follow-up study, are required to confirm this finding and
understand the extent of change in each of the fat depots
in those with a history of body fat abnormalities. Further
studies are also needed to understand the factors contrib-
uting to the differences in the change of waist circumfer-
ence in HIV-infected and uninfected patients and whether
these are attributable to antiretroviral therapy, increased
caloric intake, decreased physical activity, or other factors.
In a previous MACS analysis using the entire cohort [8],
we found that waist circumference increased more rapidly
in HIV-infected men compared to HIV-negative men after
adjustment for the effects of antiretroviral therapy, which
may suggest a difference in the effect of aging on body
composition by HIV-serostatus. Our current findings
leave open the possibility that aging-related changes in
waist circumference may be accelerated in those with lipo-
dystrophy; this should be further investigated.
The present study had several limitations. First, our cases
were defined based on clinical examination alone. In the
time since our study was designed, other studies have
defined lipodystrophy based on both patient-reported
and clinician-observed fat abnormalities[3,5,14] which
may reduce bias[26]. Second, the MACS population
includes only men and our findings are not generalizable
to women. Other studies have shown different patterns of
fat distribution in HIV-infected men and women com-
pared to gender-matched control populations [5,6,16]. In
addition, our small sample size may have limited our abil-
ity to detect small differences between the groups and pre-
cluded analyses based on further stratification of the data,
such as comparison of BMI categories. Further studies of
body composition comparing HIV-infected subjects and
HIV-uninfected controls are required, particularly longitu-
dinal studies to assess changes over time.
Conclusion
Lipoatrophy and lipohypertrophy are common in HIV-
infected individuals and are associated with increased car-
diometabolic risk and impaired quality of life. Our find-AIDS Research and Therapy 2009, 6:8 http://www.aidsrestherapy.com/content/6/1/8
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ings would suggest that even those HIV-infected without
clinical evidence of lipoatrophy have reduced subcutane-
ous and extremity fat compared to their HIV-uninfected
peers, highlighting the importance of subclinical lipoatro-
phy. Our findings would also suggest that abdominal adi-
posity increases more quickly in HIV-infected men with
clinical lipodystophy, compared to those HIV-infected
men without lipodsytrophy and HIV-uninfected men. The
mechanisms underlying this process and its effects on car-
diovascular risk require further investigation.
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